German startup Spark Microgravity to build first space-based commercial cancer lab

The American space stations under development
The German startup Spark Microgravity announced yesterday it is negotiating with two commercial space stations, one re-entry capsule company, and one French rocket startup to launch the first commercial cancer lab in space.
SPARK Microgravity is collaborating with Axiom Space and Voyager Technologies on commercial low Earth orbit (LEO) opportunities, with ATMOS Space Cargo supporting future return missions. A first flight demonstration with Swedish Space Corporation is scheduled in May. The cancer research will be launched in partnership with HyPrSpace, which developed Baguette-One, the first rocket to be launched from France.
Axiom hopes to launch its first modules in ’28, while Voyager’s Starlab station can’t launch until Starship is operational, possibly about the same time. ATMOS is a German startup developing a returnable capsule that can fly in orbit for several months. It has a deal with Hyperspace to fly a demo capsule on Baguette-1, which is a suborbital rocket.
Similar research has been done on ISS, but NASA’s rules forbid that research to produce a product for sale. Those rules won’t apply on the private stations, and Spark’s existence is a reflection of this new profit-oriented reality. Spark is going to attract investment capital from the pharmaceutical and academic communities, and thus is another profit center for the commercial space stations, outside of government funding.
The market for these new space stations is growing, making any NASA construction contracts less critical in the long run.

The American space stations under development
The German startup Spark Microgravity announced yesterday it is negotiating with two commercial space stations, one re-entry capsule company, and one French rocket startup to launch the first commercial cancer lab in space.
SPARK Microgravity is collaborating with Axiom Space and Voyager Technologies on commercial low Earth orbit (LEO) opportunities, with ATMOS Space Cargo supporting future return missions. A first flight demonstration with Swedish Space Corporation is scheduled in May. The cancer research will be launched in partnership with HyPrSpace, which developed Baguette-One, the first rocket to be launched from France.
Axiom hopes to launch its first modules in ’28, while Voyager’s Starlab station can’t launch until Starship is operational, possibly about the same time. ATMOS is a German startup developing a returnable capsule that can fly in orbit for several months. It has a deal with Hyperspace to fly a demo capsule on Baguette-1, which is a suborbital rocket.
Similar research has been done on ISS, but NASA’s rules forbid that research to produce a product for sale. Those rules won’t apply on the private stations, and Spark’s existence is a reflection of this new profit-oriented reality. Spark is going to attract investment capital from the pharmaceutical and academic communities, and thus is another profit center for the commercial space stations, outside of government funding.
The market for these new space stations is growing, making any NASA construction contracts less critical in the long run.












